Xconomy Boston

Genzyme Adds Whitworth to Board, WSJ Says

Luke Timmerman4/14/10Comments (1)

Genzyme (NASDAQ: GENZ), the Cambridge, MA-based biotech giant, has agreed to add Ralph Whitworth, the prominent San Diego activist investor, to its board of directors immediately, according to a report this evening on the Wall Street Journal’s website, which cited a person familiar with the matter. Adding Whitworth could make things more difficult for another activist shareholder, billionaire Carl Icahn, who is calling for significant change at Genzyme in the wake of its manufacturing troubles of the past year. Relational Investors, Whitworth’s firm, has a 4 percent stake in Genzyme.

Whitworth reached a “mutual cooperation” agreement with the company in January. That deal said he would support the biotech’s nominees for the board at the 2010 annual meeting scheduled for June 16, but if Whitworth wasn’t satisfied with the nominees, Genzyme would name him to the board in the fall. Whitworth, who is based in San Diego, talked about his goals for fixing things at Genzyme in this interview in January with my colleague in San Diego, Bruce Bigelow.

A Genzyme spokesman didn’t immediately respond to an e-mailed request for comment late Wednesday night.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

Comments (1)

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.